Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

I3LVS7 (I3LVS7_PIG) Sus scrofa (Pig)

Transforming protein RhoA UniProtKBInterProSTRINGInteractive Modelling

193 aa; Sequence (Fasta) ; 109 identical sequences

Available Structures

116 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Farnesylated RhoA-GDP in complex with RhoGDI-alpha, lysine acetylated at K178 Heteromer
P19803; P61586;
1-191
FAR;GDP;MG;BGC;
Assess
Double acetylated RhoGDI-alpha in complex with RhoA-GDP Heteromer
P19803; P61586;
4-193
GDP;MG;
Assess
Cryo-EM structure of the human TRPV4 - RhoA, apo condition Heteromer
P61586; Q9HBA0;
1-190
MG;GDP;
Assess
Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK2798745 Heteromer
P61586; Q9HBA0;
1-190
XPW;MG;GDP;
Assess
Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK1016790A Heteromer
P61586; Q9HBA0;
1-190
XQ3;Y01;GSP;
Assess
Crystal structure of SmgGDS-558 and farnesylated RhoA complex Heteromer
P52306; P61586;
3-191
FAR;
Assess
CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX Heteromer
P52565; P61586;
4-190
MG;GDP;
Assess
A Complex between PH Domain of p114RhoGEF and Activated RhoA Bound to a GTP Analog Heteromer
P61586; Q6P9R4;
1-181
GSP;MG;EDO;
Assess
Crystal Structure of RhoA-GDP-Pi in Complex with RhoGAP Heteromer
P61586; Q07960;
2-182
PO4;MES;GDP;MG;DTT;
Assess
CRYSTAL STRUCTURE OF HUMAN RHOA COMPLEXED WITH THE EFFECTOR DOMAIN OF THE PROTEIN KINASE PKN/PRK1 Heteromer
P61586; Q16512;
1-181
MG;GSP;
Assess
Cryo-EM structure of human TRPV4 ankyrin repeat domain in complex with GTPase RhoA Heteromer
P61586; Q9HBA0;
2-182
GDP;
Assess
Shigella IpgB2 in complex with human RhoA and GDP (complex C) Heteromer
P61586; Q9AJW7;
2-181
GDP;SO4;
Assess
Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) Heteromer
P61586; Q9AJW7;
2-181
GDP;MG;
Assess
Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex B) Heteromer
P61586; Q9AJW7;
2-181
GDP;MG;
Assess
Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA Heteromer
P61586; Q9NZN5;
2-181
PO4;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z108545814 Heteromer
P61586; Q92974;
3-181
YX2;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1273312142 Heteromer
P61586; Q92974;
3-181
DMS; 14×FMT;Z4X;
Assess
The DH domain of ARHGEF2 bound to RhoA Heteromer
P61586; Q92974;
3-181
DMS; 15×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079512010 Heteromer
P61586; Q92974;
3-181
UWS;DMS; 15×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079168976 Heteromer
P61586; Q92974;
3-181
YXK;DMS; 10×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100643660 Heteromer
P61586; Q92974;
3-181
LFO;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270087714 Heteromer
P61586; Q92974;
3-181
Z5Z;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100642432 Heteromer
P61586; Q92974;
3-181
WJ7;DMS; 15×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474512 Heteromer
P61586; Q92974;
3-181
H04;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269220427 Heteromer
P61586; Q92974;
3-181
Z2Z;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198180782 Heteromer
P61586; Q92974;
3-181
YXU;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1041785508 Heteromer
P61586; Q92974;
3-181
K34;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1137725943 Heteromer
P61586; Q92974;
3-181
YXB;DMS; 10×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 Heteromer
P61586; Q92974;
3-181
LXA;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104479710 Heteromer
P61586; Q92974;
3-181
DMS; 12×FMT;YXH;
Assess
Crystal Structure of RhoA.GDP.MgF3-in Complex with RhoGAP Heteromer
P61586; Q07960;
3-181
MG;GDP;MGF;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1102357527 Heteromer
P61586; Q92974;
3-181
YX6;DMS; 11×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148747945 Heteromer
P61586; Q92974;
3-181
WKY;DMS; 10×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1192341021 Heteromer
P61586; Q92974;
3-181
ZT7;DMS;FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 Heteromer
P61586; Q92974;
3-181
LXA;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102209-001 Heteromer
P61586; Q92974;
3-181
DMS; 10×FMT;ZGF;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474228 Heteromer
P61586; Q92974;
3-181
DMS; 12×FMT;60P;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416193393 Heteromer
P61586; Q92974;
3-181
Z6I;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1216861874 Heteromer
P61586; Q92974;
3-181
YYI;DMS;FMT;
Assess
A Complex between PH Domain of LbcRhoGEF (AKAP-Lbc) and Activated RhoA Bound to a GTP Analog Heteromer
P61586; Q12802;
3-181
MG;GSP;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148165337 Heteromer
P61586; Q92974;
3-181
YG5;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102236-001 Heteromer
P61586; Q92974;
3-181
DMS; 11×FMT;ZGK;
Assess
AKAP13 (AKAP-Lbc) RhoGEF domain in complex with RhoA Heteromer
P61586; Q12802;
3-181
GDP;SO4;EDO;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102197-001 Heteromer
P61586; Q92974;
3-181
DMS; 10×FMT;ZG6;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1037511924 Heteromer
P61586; Q92974;
3-181
YXO;DMS; 10×FMT;
Assess
A Complex between PH Domain of p190RhoGEF and Activated RhoA Bound to a GTP Analog Heteromer
P61586; Q8N1W1;
3-181
MG;GSP;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102253-001 Heteromer
P61586; Q92974;
3-181
ZGQ;DMS; 10×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269184613 Heteromer
P61586; Q92974;
3-181
Z2F;DMS;FMT;
Assess
Transition state analogue of small G protein in complex with relevant GAP Heteromer
P61586; Q07960;
3-181
GDP;MGF;MG;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1262549981 Heteromer
P61586; Q92974;
3-181
Z1L;DMS; 11×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198316457 Heteromer
P61586; Q92974;
3-181
YXY;DMS; 11×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102116-001 Heteromer
P61586; Q92974;
3-181
DMS;FMT;ZG0;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102113-001 Heteromer
P61586; Q92974;
3-181
DMS; 11×FMT;ZEK;
Assess
Structure of TcdA GTD in complex with RhoA Heteromer
P16154; P61586;
2-180
UPG;MN;SO4;GDP;MG;
Assess
Crystal structure of the complex between the human RhoA and Rho-binding domain of human ROCKI Heteromer
P61586; Q13464;
3-181
MG;GNP;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102179-001 Heteromer
P61586; Q92974;
3-181
DMS;FMT;T7Y;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102141-001 Heteromer
P61586; Q92974;
3-181
DMS;FMT;ZFI;
Assess
Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA Heteromer
O15085; P61586;
3-181
MG;GSP;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102245-001 Heteromer
P61586; Q92974;
3-181
DMS;FMT;KLU;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z133716556 Heteromer
P61586; Q92974;
3-180
Z3H;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1575337975 Heteromer
P61586; Q92974;
3-180
ZC9;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1217131798 Heteromer
P61586; Q92974;
3-180
YZK;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1493056027 Heteromer
P61586; Q92974;
3-180
DMS; 14×FMT;Z9I;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z165170770 Heteromer
P61586; Q92974;
3-180
W0Y;DMS; 11×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1267800292 Heteromer
P61586; Q92974;
3-180
O2A;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1251207602 Heteromer
P61586; Q92974;
3-180
RWS;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270393711 Heteromer
P61586; Q92974;
3-180
Z5C;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1565771450 Heteromer
P61586; Q92974;
3-180
VW7;DMS; 10×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416571195 Heteromer
P61586; Q92974;
3-180
Z7T;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1449748885 Heteromer
P61586; Q92974;
3-180
WZY;DMS; 14×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102102-001 Heteromer
P61586; Q92974;
3-180
ZE9;DMS; 13×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1545313172 Heteromer
P61586; Q92974;
3-180
LWA;DMS; 14×FMT;
Assess
GTPase IN COMPLEX WITH GDP.MGF3- Heteromer
P61586; Q07960;
3-180
GDP;MGF;MG;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509195674 Heteromer
P61586; Q92974;
3-180
ZA9;DMS; 11×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102281-001 Heteromer
P61586; Q92974;
3-180
ZGX;DMS; 11×FMT;
Assess
CRYSTAL STRUCTURE OF HUMAN RHOA IN COMPLEX WITH DH/PH FRAGMENT OF THE GUANINE NUCLEOTIDE EXCHANGE F… Heteromer
P61586; Q7Z628;
3-180
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1255459547 Heteromer
P61586; Q92974;
3-180
Z0I;DMS; 12×FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509257513 Heteromer
P61586; Q92974;
3-180
ZBH;DMS; 11×FMT;
Assess
Crystal structure of the ternary complex between the human RhoA, its inhibitor and the DH/PH domain… Heteromer
O15085; P61586;
3-180
GOL;RA0;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z57899718 Heteromer
P61586; Q92974;
3-180
APY;DMS;FMT;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1203730981 Heteromer
P61586; Q92974;
3-180
ZCI;DMS;FMT;
Assess
Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.Mg… Heteromer
P61586; Q07960;
3-180
MG;GDP;MGF;
Assess
Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain Heteromer
P61586; Q13459;
3-180
MGF;MG;GDP;
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z131833926 Heteromer
P61586; Q92974;
3-180
DMS;FMT;Z3O;
Assess
Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF Heteromer
O15085; P61586;
3-180
Assess
Crystal structure of the complex between the human RhoA and the DH/PH domain of human ARHGEF11 Heteromer
O15085; P61586;
3-180
GOL;
Assess
Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA Heteromer
P61586; Q64096;
3-180
Assess
Crystal Structure of the DH/PH fragment of PDZRHOGEF with N-terminal regulatory elements in complex… Heteromer
O15085; P61586;
3-180
Assess
ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z4605084898 Heteromer
P61586; Q92974;
3-180
DMS;FMT;ZDL;
Assess
Crystal structure of RhoA.GDP.MgF3 in complex with GAP domain of ArhGAP20 Heteromer
P61586; Q9P2F6;
4-180
GDP;MG;MGF;
Assess
RHO/RHOGAP/GDP(DOT)ALF4 COMPLEX Heteromer
P61586; Q07960;
3-179
MG;ALF;GDP;
Assess
p190A GAP domain complex with RhoA Heteromer
P61586; P81128;
4-180
CL;GDP;MG;MGF;
Assess
Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution Heteromer
P61586; Q9NQW6;
4-180
GTP;MG;
Assess
The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-bound state) Heteromer
P61586; Q8KNY0;
3-179
GSP;MG;NAI;EDO;
Assess
The complex structure of C3cer exoenzyme and GDP bound RhoA (NADH-bound state) Heteromer
P61586; Q8KNY0;
3-179
GDP;MG;NAI;EDO;
Assess
Crystal Structure of p63RhoGEF complex with Galpha-q and RhoA Heteromer
P21279; P61586; Q86VW2;
4-180
ALF;MG;GDP;
Assess
The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-free state) Heteromer
P61586; Q8KNY0;
4-179
GSP;MG;EDO;
Assess
Crystal Structure of human RhoGAP mutated in its arginin finger (R85A) in complex with RhoA.GDP.AlF… Heteromer
P61586; Q07960;
5-179
MG;GDP;ALF;
Assess
Crystal structure of the fusion protein linked by RhoA and the GAP domain of MgcRacGAPmonomer2-193
MG;AF3;GDP;
Assess
An open conformation Form 1 of switch II for RhoAmonomer1-180
GDP;MG;
Assess
An open conformation Form2 of switch II for RhoA GDP-bound statemonomer1-180
GOL;GDP;MG;
Assess
Crystal structure of RhoA-GDP with novel Switch I conformationmonomer3-181
GDP;MG;DIO;
Assess
RhoA GDP with novel switch II conformationmonomer3-181
MG;GDP;
Assess
Crystal structure of an inactive state of GMPPNP-bound RhoAmonomer3-181
GNP;MG;DIO;
Assess
Crystal structure of oncogenic RhoA mutant G14V complexed with GDPmonomer3-181
GDP;MG;DIO;
Assess
Small GTPase RhoA mutant 2monomer3-181
GDP;MG;
Assess
Crystallization and preliminary X-ray crystallographic analysis of a small GTPase RhoAmonomer2-180
MG;GDP;
Assess
Crystal structure of RhoA protein with covalent inhibitor DC-Rhoinmonomer3-181
GDP;8ZO;
Assess
RhoGAP domain of ARAP3 in complex with RhoA in the transition statemonomer2-180
GDP;MG;ALF;
Assess
Small GTPase mutant ARGmonomer3-180
GDP;MG;
Assess
CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDPmonomer3-180
GDP;
Assess
Crystal structure of Yersinia Afp18-modified RhoAmonomer3-180
GDP;SO4;NDG;
Assess
HUMAN RHOA COMPLEXED WITH GTP ANALOGUEmonomer4-181
MG;GSP;
Assess
Crystal structure of GDP bound RhoA proteinmonomer4-180
GDP;
Assess
Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L)monomer4-180
MG;GNP;DIO;
Assess
CRYSTAL STRUCTURE OF THE HUMAN RHOA/GDP COMPLEXmonomer4-180
MG;GDP;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5fr1.1.Amonomer0.844-193
GDP;100.00
Assess